Chất lượng cuộc sống bệnh nhân ung thư phổi giai đoạn IV điều trị thuốc tyrosine kinase thế hệ I

Advanced Non-Small Cell Lung Cancer (NSCLC) at stage IV presents significant therapeutic challenges, despite numerous advancements in treatment options. First-generation Tyrosine Kinase Inhibitors (TKIs) are frequently chosen in clinical practice due to their favorable cost-effectiveness, high efficacy, and good tolerability, particularly for patients with EGFR gene mutations. Beyond extending survival, enhancing the Quality of Life (QoL) for these patients is a crucial clinical consideration. However, there is a noticeable scarcity of comprehensive studies addressing this vital aspect within the Vietnamese healthcare context. This study aims to evaluate the QoL of stage IV lung cancer patients undergoing treatment with first-generation TKIs, thereby filling this research gap and informing clinical practice.

Oncologists, pulmonologists, medical researchers, and healthcare professionals specializing in lung cancer treatment and patient quality of life.

This prospective descriptive study investigated the Quality of Life (QoL) in 51 stage IV Non-Small Cell Lung Cancer (NSCLC) patients receiving first-generation Tyrosine Kinase Inhibitors (TKIs) at K Hospital in Vietnam from March 2023 to August 2024. Patient QoL was comprehensively assessed using the EORTC QLQ-C30 and EORTC QLQ-LC13 questionnaires, with evaluations conducted at baseline, 1 month, and 3 months post-treatment. The findings revealed statistically significant improvements in most functional aspects of QoL, including physical activities, social roles, social integration, and emotional functioning, after both 1 and 3 months of treatment, with the exception of cognitive ability. Symptom-specific analysis from the EORTC QLQ-LC13 showed significant reductions in shortness of breath, cough, and pain over the same periods. Conversely, symptoms such as mouth pain, hair loss, and peripheral neuropathy did not show statistically significant changes. Overall, the first-generation TKI treatment regimen demonstrably leads to significant enhancements in both symptom control and the general Quality of life for stage IV lung cancer patients. Furthermore, while common side effects like skin rash and diarrhea were noted, they were predominantly mild (Grade 1), indicating good tolerability. No significant differences in QoL improvement were observed between Erlotinib and Gefitinib, except for a more pronounced improvement in cough with Erlotinib. These insights are invaluable for clinicians in Vietnam, providing a localized understanding of TKI efficacy beyond survival benefits and highlighting the importance of holistic patient care.